Novo Nordisk cuts ribbon on $225M U.S. headquarters; Novartis embarks on $60M vaccines expansion in NC;

 @FiercePharma: Novartis forges ahead with expansion at North Carolina vaccines campus, with $60M tech building. Report | Follow @FiercePharma

 @EricPFierce: $65 million DSM cell culture plant in Brisbane part of Australia's $345 million Translational Research Institute. Story | Follow @EricPFierce

> Novo Nordisk ($NVO) opened its new, $225 million U.S. headquarters, designed to cut energy costs by 30% and improve innovation and employee wellness. Report

> Novartis ($NVS) forged ahead with an expansion at its Holly Springs, NC, vaccines campus, with plans for a $60 million technical services building. Report

> U.K. cost-effectiveness watchdogs recommended Bayer's anticoagulant drug Xarelto for new indications in pulmonary embolism and deep vein thrombosis. Report

> Nearly 30% of women fail to pick up their prescriptions for osteoporosis drugs, a Kaiser Permanente study found. Report

> Finland's Orion said first-quarter profits fell on increasing generic competition for its Parkinson's drugs. Report

> Sucampo Pharmaceuticals won the FDA nod for a new indication for its constipation treatment Amitiza. Report

Medical Device News

 @FierceMedDev: CareFusion endures another Class I pump recall. News | Follow @FierceMedDev

 @MarkHFierce: Just attended our FierceBiotech breakfast and covered an R&D panel. Great ideas, but will they boost success rates? | Follow @MarkHFierce

 @DamianFierce: Roche Diagnostics is axing 170 jobs as its dissolves Applied Science biz. News | Follow @DamianFierce

> Cervel Neurotech snags $14.1M for anti-depression device. More

> Patent suit loss tanks Illumina's strong sales quarter. Story

> Report: Electrophysiology device sales grow fastest in Asia. Item

Biotech News

 @FierceBiotech: E&Y: Biotech budget hawks rule the roost in year of mixed performance. Report | Follow @FierceBiotech

 @RyanMFierce: RBC analyst Michael Ye says BMS' PhII data for all-oral reg isn't much of a threat to Gilead. So, again, Gilead is still the frontrunner.  | Follow @RyanMFierce

> Chicago uses its turn in BIO spotlight to promote incubator plans. Story

> GlaxoSmithKline and Avalon Ventures forge $495M biotech startup alliance. News

> Moody's: Deep-pocketed pharma giants poised to boost M&A activity this year. More

Pharma Manufacturing News

> Novartis expanding U.S. vaccine complex. Item

> U.S. lawmakers take another shot at mandating drug tracking system. More

> Fujifilm expands former Merck biologics plant in U.K. News

> DSM sets June launch for Australian biologics plant. Article

Biotech Research News

 @EmilyMFierce: Intel, Oregon Health & Science University partner on genetic profiling project. More | Follow @EmilyMFierce

> Antibody genes linked to ethnicity. Item

> Autistic behavior has genetic basis in mice. Article

> Radioactive bacteria treatment stops metastasis in mice. More

> Columbia researchers identify hundreds of potential metabolic cancer targets. Story

And finally ... Researchers are working on quick-acting treatments for depression. Report

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.